Figure 2. Responses to treatment after haploidentical-BMT. Shown are PET-CT images performed after each respective treatment (Post-Rx). Post-Dx mo. indicate months after initial diagnosis. (A) disease progression after haplo-BMT; (B) mixed response with decreased mediastinal and chest wall FDG avidity but new focal subpleural avid areas, new mildly avid pulmonary nodules and a new focal lesion in the hepatic dome during second cycle of blinatumomab (Blina) and following DLI but before progression to grade III GvHD; (C) sustained tumor response with intense FDG uptake throughout the small and large colon compatible with intestinal graft versus host disease while on tapering doses of prednisone and cyclosporine A; (D) complete metabolic response with less intestinal FDG uptake but evidence of esophangitis and gastritis after discontinuing immunosuppression; (E) disease recurrence after stopping blinatumomab and resolution of GvHD